Trim11 antibody - C-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q99PQ2 |
Other Accession | NM_053168, NP_444398 |
Reactivity | Human, Mouse, Rat, Rabbit, Horse, Bovine, Guinea Pig, Dog |
Predicted | Rat, Rabbit, Pig, Horse, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 52kDa |
Gene ID | 94091 |
---|---|
Other Names | E3 ubiquitin-protein ligase TRIM11, 6.3.2.-, Tripartite motif-containing protein 11, Trim11 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-Trim11 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | Trim11 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Trim11 |
---|---|
Function | E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX (PubMed:18628401). Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis (PubMed:18628401). May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences (PubMed:18628401). May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway (PubMed:12670303). Mediates MED15 ubiquitination leading to proteasomal degradation (By similarity). May contribute to the innate restriction of retroviruses (PubMed:18248090). Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression (PubMed:18248090). Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain (PubMed:18248090). May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle (PubMed:18248090). Acts as an inhibitor of the AIM2 inflammasome by promoting autophagy-dependent degradation of AIM2 (By similarity). Mechanistically, undergoes autoubiquitination upon DNA stimulation, promoting interaction with AIM2 and SQSTM1/p62, leading to AIM2 recruitment to autophagosomes (By similarity). |
Cellular Location | Cytoplasm. Nucleus. Note=In the nucleus, colocalizes with PAX6. |
Tissue Location | Expressed in embryonic central nervous system (CNS), kidney, thymus and gut. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.